Advertisement

Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy?

  • M. L. Tanda
  • E. Piantanida
  • E. Masiello
  • C. Cusini
  • L. BartalenaEmail author
Comment
  • 15 Downloads

Graves’ orbitopathy (GO) is the main non-thyroidal expression of Graves’ disease [1]. Management of moderate-to-severe and active forms of the disease remains a major and not completely solved therapeutic challenge and dilemma [2]. Glucocorticoids are, for the time being, the first-line treatment, usually given intravenously in 12 weekly infusions, with a cumulative dose of 2.5–7.5 g of methylprednisolone, more commonly 4.5 g [2]. Intravenous glucocorticoids are effective, particularly in inactivating the disease, but some features of GO, namely exophthalmos and longstanding extraocular muscle restriction, are not very responsive [2]. Treatment is more effective if duration of GO is < 1 year [1]. Relapses after treatment withdrawal are not infrequent [2]. In addition, large doses of glucocorticoids are needed, and this may cause severe adverse events, including liver toxicity, hypertension, diabetes, psychosis [2]. Therefore, the addition of a second drug aimed at reducing the dose of...

Keywords

Graves’ orbitopathy Intravenous glucocorticoids Methotrexate Cyclosporine 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This paper did not involve patients.

References

  1. 1.
    Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700CrossRefGoogle Scholar
  2. 2.
    Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, on behalf of the European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European group on Graves’ orbitopathy Guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26CrossRefGoogle Scholar
  3. 3.
    Prummel MF, Mourits P, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM (1989) Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 321:1353–1359CrossRefGoogle Scholar
  4. 4.
    Tanda ML, Bartalena L (2012) Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab 97:3857–3865CrossRefGoogle Scholar
  5. 5.
    Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Fuhrer D, Salvi M, Currò N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, for the European Group on Graves’ Orbitopathy (EUGOGO) (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomized, observer-masked, multicentre study. Lancet Diabetes Endocrinol 6:287–298CrossRefGoogle Scholar
  6. 6.
    Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, Yarrow S, Garrott H, Herbert HM, Dick AD, Cook A, Gattamaneni R, Jain R, Olver J, Hurel SJ, Bremner F, Drummond SR, Kemp E, Ritchie BM, RumsEy N, Morris D, Lane C, Palanappian N, Li C, Pell J, Hills R, Ezra DG, Potts MJ, Jackson S, Rose GE, Plowman N, Bunce C, Uddin JM, Lee RWJ, Dayan CM (2018) Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomized controlled trial. Lancet Diabetes Endocrinol 6:299–309CrossRefGoogle Scholar
  7. 7.
    Sipkova Z, Insull EA, David J, Turner HE, Karen S, Norris JH (2018) Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol 89:834–839CrossRefGoogle Scholar
  8. 8.
    Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:885–887CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2019

Authors and Affiliations

  • M. L. Tanda
    • 1
  • E. Piantanida
    • 1
  • E. Masiello
    • 1
  • C. Cusini
    • 1
  • L. Bartalena
    • 1
    Email author
  1. 1.Endocrine Unit, ASST dei Sette Laghi, Department of Medicine and SurgeryUniversity of InsubriaVareseItaly

Personalised recommendations